(NYSE: ZTS) Zoetis's forecast annual revenue growth rate of 1.01% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 7.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 12.32%.
Zoetis's revenue in 2026 is $9,508,000,000.On average, 19 Wall Street analysts forecast ZTS's revenue for 2026 to be $3,838,874,956,856, with the lowest ZTS revenue forecast at $3,677,973,762,644, and the highest ZTS revenue forecast at $4,228,938,457,976. On average, 19 Wall Street analysts forecast ZTS's revenue for 2027 to be $3,867,723,403,293, with the lowest ZTS revenue forecast at $3,587,365,261,863, and the highest ZTS revenue forecast at $4,480,448,152,969.
In 2028, ZTS is forecast to generate $3,999,369,834,921 in revenue, with the lowest revenue forecast at $3,658,470,587,588 and the highest revenue forecast at $4,738,458,906,314.